undamentalytics Newsletter
Sign in

Astrana Health, Inc. (ASTH) stock

Add to watchlist

Add holding +

NASDAQ: ASTH Nasdaq Health Care Services Next results ~November 5, 2026

C+ Fundamentals grade

Astrana Health, Inc. is a US-listed company in the health care services industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: after-tax interest is 75% of the cash flow left for shareholders; our flat discount rate doesn't yet reflect debt this heavy.

Price vs value

Under review: after-tax interest is 75% of the cash flow left for shareholders; our flat discount rate doesn't yet reflect debt this heavy. We'll show the comparison once resolved.

Astrana Health, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Funds135 adding, 66 cuttingOf 33 active managers that changed their stake, 18 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Astrana Health files

Where Astrana Health stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $3.84bn, up 58.9% on a year earlier, faster than the 56.7% growth a quarter earlier. That growth ranks 1 of 21 among the health care services companies we cover. Free-cash-flow margin fell to 2.5% from 5.0% a year earlier. Against its peers on growth, profitability, cash generation and balance sheet, it grades C. It passes 1 of our 7 financial-health checks.

Our model value for Astrana Health is under review, so past values are not shown until it is resolved.

Source: 10-Q filed August 10, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 5, 2026 (estimated)

Astrana Health, Inc.'s trailing-twelve-month revenue grew 58.9% year on year, with a free-cash-flow margin of 2.5%. Where it stands out: revenue growth of 58.9% ranks 2 of 41 health care services companies we cover.

Our discounted-cash-flow model values the business at ~$64 per share in the base case (~$46–$88 across growth scenarios) — model values under stated assumptions, not a price target.

Current signal Free cash flow diverging from earnings: TTM free cash flow fell 22.2% while net income grew 60.5%: a 83pp divergence.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 58.9% over the last 12 months, against a median of 7.3% for health care services companies we cover.
  • Beating expectations. Earnings per share beat the analysts' consensus estimate in each of the last four quarters.
  • Estimates rising. Analysts' consensus for next year's earnings per share has risen 6.6% over 90 days.

Things to watch

  • Results due soon. Results are expected around 5 November; the share price can move sharply on the day.
  • High earnings multiple. The shares trade at 45 times the last 12 months' earnings, so expectations are demanding.
  • Volatile shares. Over the past year the shares showed annualised volatility of 67% and a beta of 0.6 against the S&P 500.
  • Below peers: long-term debt as % of assets. Long-term debt as % of assets of 38.7% ranks 24 of 31 health care services companies we cover (median 27.7%).
  • Heavily shorted. 11.6% of the shares available to trade are sold short (6.9 days of average volume to cover).

Latest results: FY2026 Q2

Filed August 10, 2026
Earnings per share
$0.80 against an average estimate of $0.73: beat by 9.6%
Revenue
$973m, up 48.5% on a year earlier
Share reaction
-0.2% in the first session after the results on August 6, 2026, against +0.5% for the S&P 500
Guidance given
total revenue $1,000m to $1,030m (three months ending September 30, 2026); total revenue $3,800m to $4,100m (year ending December 31, 2026)
Next report
November 5, 2026; average EPS estimate $0.88

Astrana Health's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+1.0%
  • 1 week-0.9%
  • 1 month+2.8%
  • This year+48.6%
  • 1 year+18.2%
  • 5 years-50.8%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$3.8B
Operating margin
2.6%
Net margin
1.1%
EPS (TTM, diluted)
$0.82

Growth

Revenue growth
+58.9%
Change in growth rate
+2.2 pts
Share count change
+1.8%

Cash

Free cash flow (TTM)
$94.4M
FCF margin
2.5%
Stock pay % of revenue
1.1%

Earnings

Last results
August 6, 2026
Next results (est.)
November 5, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Partnership
  2. Announcement
  3. Announcement
  4. Results
  5. Guidance
  6. Announcement
  7. Announcement
  8. Announcement

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Astrana Health, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: held for review: after-tax interest is 75% of the cash flow left for shareholders; our flat discount rate doesn't yet reflect debt this heavy.

The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.

Valuation models

We value Astrana Health, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 9.1%: the 10-year Treasury yield (4.9%) plus a beta of 0.93 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Cash-flow model (DCF) Free cash flow to the firm (after stock pay, with after-tax interest added back), grown then faded to 2.5%, discounted at 8.5% as the firm rate, less debt and other claims. — Does not apply: This model is withheld pending its input or assumption review.
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. — Does not apply: This model is withheld pending its input or assumption review.
Forward price-to-earnings vs peers Next year's consensus earnings per share times peers' typical (harmonic-mean) forward price-to-earnings. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$68 ~$55–$100 Included
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. ~$15 ~$10–$21 Left out: far from the other models (more than 3x away from their median)
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. ~$13 ~$11–$16 Left out: far from the other models (more than 3x away from their median)
Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. — Combined value withheld. Review the individual models and their assumptions.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Astrana Health, Inc. with Health Care Services in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 2016201720182019202020212022202320242025Now
Share price$7.50$24.00$19.85$18.41$18.27$73.48$29.59$38.30$31.53$24.81$36.88
Market value$210m$688m$753m$670m$684m$3.3bn$1.3bn$1.8bn$1.5bn$1.2bn$1.8bn
+ Net debt (− = net cash)−$55m−$95m−$107m$148m$52m−$45m−$81m−$12m$150m$623m$548m
Enterprise value$155m$593m$646m$818m$736m$3.3bn$1.3bn$1.8bn$1.7bn$1.8bn$2.4bn
Multiples
Price / sales 0.7x1.9x1.4x1.2x1.0x4.3x1.2x1.3x0.7x0.4x0.5x
Price / earnings 18.3x26.7x69.5x47.5x18.2x48.4x29.9x29.6x35.1x54.5x45.0x
Price / free cash flow 11.3x13.8x30.9x53.1x15.2x65.3x22.8x45.3x34.2x11.7x19.3x
EV / EBITDA 5.2x10.9x6.0x16.1x7.4x28.4x10.4x17.4x14.2x14.9x14.5x

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

36 /100

Weak moat

How hard Astrana Health's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 5 / 20

    Net income has been a median 4.6% of total assets over 10 years.

  • Durability 6 / 20

    Operating margin has been a median 8.4%; its worst year was 2.6%.

  • Cash conversion 11 / 20

    Free cash flow was positive in 9 of 10 years, at a median 4.9% of revenue.

  • Discipline 10 / 20

    The diluted share count rose 20.4% over five years; stock-based pay has been a median 0.9% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (40 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 5, 2026, after the close. Analysts expect revenue of $1.0bn and EPS of $0.88 (range $0.83 to $0.91) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current $3.07 +45% $4.0bn +25%
Next $3.64 +19% $4.4bn +10%

Next year's EPS estimate has moved +6.6% in 90 days, across 3 analysts.

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +5.0% on 90 days ago. In the last 30 days, 2 analysts raised Astrana Health, Inc.'s forecast and 0 cut it.

Consensus EPS forecast Astrana Health, Inc., last 90 days
$2.80 $3.00 $3.20 $3.40 $3.60 $3.80 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: $2.92 Current fiscal year, 60 days ago: $2.92 Current fiscal year, 30 days ago: $3.04 Current fiscal year, 7 days ago: $3.04 Current fiscal year, Now: $3.07 $3.07 Next fiscal year, 90 days ago: $3.41 Next fiscal year, 60 days ago: $3.42 Next fiscal year, 30 days ago: $3.54 Next fiscal year, 7 days ago: $3.54 Next fiscal year, Now: $3.64 $3.64

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago $2.92$3.41
60 days ago $2.92$3.42
30 days ago $3.04$3.54
7 days ago $3.04$3.54
Now $3.07$3.64

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 $0.73 $0.80 +9.6%
Mar 2026 $0.65 $0.74 +13.9%
Dec 2025 $0.33 $0.42 +28.6%
Sept 2025 $0.61 $0.67 +10.7%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, August 6, 2026
  • Total revenue year ending December 31, 2026 $3,800m to $4,100m Maintained
    “Total revenue $ 1,000 $ 1,030 $ 3,800 $ 4,100” source
  • Total revenue three months ending September 30, 2026 $1,000m to $1,030m New
    “Total revenue $ 1,000 $ 1,030 $ 3,800 $ 4,100” source
  • Adjusted EBITDA year ending December 31, 2026 $255m to $280m Non-GAAP Raised
    “Adjusted EBITDA $ 72.5 $ 77.5 $ 255 $ 280” source
  • Free cash flow year ending December 31, 2026 $105m to $133m Non-GAAP Maintained
    “Free cash flow $ 105 $ 132.5” source
  • Adjusted EBITDA three months ending September 30, 2026 $72.5m to $77.5m Non-GAAP New
    “Adjusted EBITDA $ 72.5 $ 77.5 $ 255 $ 280” source

Figures and quotations are management's, copied from the company's own press release (SEC 8-K exhibit) and checked word for word against it. Forward-looking statements are the company's expectations, not ours and not advice; guidance can change or be missed.

Analyst recommendations

11 analysts, Nov 2026
Buy1091%
Hold19%
Sell00%

Monthly trend

  1. Nov 202628111
  2. Oct 202628111
  3. Sep 202627110

Counts of recommendations published by analysts covering Astrana Health, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
11.6%
of tradable shares
Days to cover
6.9
at average volume
Short interest, 1 month
−8%
to October 15, 2026
Held by institutions
67%
of shares
Held by insiders
22.8%
of shares
Employees
3,000
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months +18.2%

$31.21 on October 31, 2025 to $36.88

ThenNowEffect
Revenue (last 12 months) $2.4bn $3.8bn +58.9%
Net margin 1.0% 1.1% +1.0%
P/E multiple 60.1x 45.0x −25.1%
Share count 49m 49m −1.7%

Biggest factor: revenue.

Last 3 years +15.4%

$31.97 on November 3, 2023 to $36.88

ThenNowEffect
Revenue (last 12 months) $1.3bn $3.8bn +196.5%
Net margin 3.5% 1.1% −70.1%
P/E multiple 32.2x 45.0x +40.0%
Share count 46m 49m −7.0%

Biggest factor: net margin.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
ASTH+302%−60%+29%−18%−21%+49%
Industry peers (median)−3%−25%+6%−6%−6%+15%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
ASTH75%42%58%33%58%64%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
ASTH−44%−63%−27%−50%−48%−38%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 2, 2015: 85% from November 16, 2021 to February 12, 2026. Getting back needed a 558% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$18.16 – $49.81
From 52-week high
−26.0%
vs 50-day average
−0.4%
vs 200-day average
+8.8%
Volatility (1 year)
67%
Beta vs S&P 500
0.59

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
5 up, 7 down
typical move ±12.2%
After a week
7 up, 5 down
typical move ±15.4%
After a month
6 up, 6 down
typical move ±16.6%
Results releasedNext dayS&P 500 next day5 days21 days
August 6, 2026 −0.2% +0.5% +5.5% +7.4%
May 7, 2026 +11.5% +0.5% +11.1% +8.9%
March 2, 2026 +20.6% −0.8% +21.6% +20.6%
November 6, 2025 −23.2% −1.0% −34.1% −33.8%
August 7, 2025 +28.7% +0.7% +35.4% +35.3%
July 2, 2025 +0.9% +1.2% +2.2% −13.9%
May 8, 2025 −7.6% +0.6% −15.8% −21.3%
February 27, 2025 −27.7% −0.1% −22.5% −13.0%
November 7, 2024 −21.1% +1.2% −29.6% −32.7%
August 7, 2024 −1.5% +1.6% −2.1% +0.1%
May 7, 2024 −0.6% +0.1% +4.4% +8.0%
February 27, 2024 +2.3% +0.1% +1.0% −3.9%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Astrana Health, Inc. in five measures

Fundamentals grade C+
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Astrana Health, Inc.
$0 $1B $2B $3B $4B FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $1.3B Revenue (TTM), FY23 Q4: $1.4B Revenue (TTM), FY24 Q1: $1.5B Revenue (TTM), FY24 Q2: $1.6B Revenue (TTM), FY24 Q3: $1.7B Revenue (TTM), FY24 Q4: $2B Revenue (TTM), FY25 Q1: $2.3B Revenue (TTM), FY25 Q2: $2.4B Revenue (TTM), FY25 Q3: $2.9B Revenue (TTM), FY25 Q4: $3.2B Revenue (TTM), FY26 Q1: $3.5B Revenue (TTM), FY26 Q2: $3.8B $3.8B

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $1.3B
FY23 Q4 $1.4B
FY24 Q1 $1.5B
FY24 Q2 $1.6B
FY24 Q3 $1.7B
FY24 Q4 $2B
FY25 Q1 $2.3B
FY25 Q2 $2.4B
FY25 Q3 $2.9B
FY25 Q4 $3.2B
FY26 Q1 $3.5B
FY26 Q2 $3.8B
Revenue growth, TTM YoY Astrana Health, Inc.
0% 20% 40% 60% 80% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: 27.1% Revenue growth, TTM YoY, FY23 Q4: 21.2% Revenue growth, TTM YoY, FY24 Q1: 19.3% Revenue growth, TTM YoY, FY24 Q2: 22.8% Revenue growth, TTM YoY, FY24 Q3: 29.7% Revenue growth, TTM YoY, FY24 Q4: 46.7% Revenue growth, TTM YoY, FY25 Q1: 54.8% Revenue growth, TTM YoY, FY25 Q2: 52.0% Revenue growth, TTM YoY, FY25 Q3: 68.2% Revenue growth, TTM YoY, FY25 Q4: 56.4% Revenue growth, TTM YoY, FY26 Q1: 56.7% Revenue growth, TTM YoY, FY26 Q2: 58.9% 58.9%

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 27.1%
FY23 Q4 21.2%
FY24 Q1 19.3%
FY24 Q2 22.8%
FY24 Q3 29.7%
FY24 Q4 46.7%
FY25 Q1 54.8%
FY25 Q2 52.0%
FY25 Q3 68.2%
FY25 Q4 56.4%
FY26 Q1 56.7%
FY26 Q2 58.9%
Operating margin (TTM) Astrana Health, Inc.
0% 2% 4% 6% 8% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: 7.6% Operating margin (TTM), FY23 Q4: 6.1% Operating margin (TTM), FY24 Q1: 6.4% Operating margin (TTM), FY24 Q2: 6.0% Operating margin (TTM), FY24 Q3: 4.9% Operating margin (TTM), FY24 Q4: 4.4% Operating margin (TTM), FY25 Q1: 3.5% Operating margin (TTM), FY25 Q2: 2.9% Operating margin (TTM), FY25 Q3: 2.1% Operating margin (TTM), FY25 Q4: 2.5% Operating margin (TTM), FY26 Q1: 2.5% Operating margin (TTM), FY26 Q2: 2.6% 2.6%

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 7.6%
FY23 Q4 6.1%
FY24 Q1 6.4%
FY24 Q2 6.0%
FY24 Q3 4.9%
FY24 Q4 4.4%
FY25 Q1 3.5%
FY25 Q2 2.9%
FY25 Q3 2.1%
FY25 Q4 2.5%
FY26 Q1 2.5%
FY26 Q2 2.6%
FCF margin (TTM) Astrana Health, Inc.
0% 5% 10% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: 8.4% FCF margin (TTM), FY23 Q4: 2.9% FCF margin (TTM), FY24 Q1: 3.0% FCF margin (TTM), FY24 Q2: 3.1% FCF margin (TTM), FY24 Q3: 4.1% FCF margin (TTM), FY24 Q4: 2.2% FCF margin (TTM), FY25 Q1: 2.3% FCF margin (TTM), FY25 Q2: 5.0% FCF margin (TTM), FY25 Q3: 3.3% FCF margin (TTM), FY25 Q4: 3.3% FCF margin (TTM), FY26 Q1: 4.4% FCF margin (TTM), FY26 Q2: 2.5% 2.5%

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 8.4%
FY23 Q4 2.9%
FY24 Q1 3.0%
FY24 Q2 3.1%
FY24 Q3 4.1%
FY24 Q4 2.2%
FY25 Q1 2.3%
FY25 Q2 5.0%
FY25 Q3 3.3%
FY25 Q4 3.3%
FY26 Q1 4.4%
FY26 Q2 2.5%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q, 10-Q/A, 10-QT. Generated November 3, 2026. Definitions in our methodology.

Where the money goes

FY2025, from the 10-K

Each dollar Astrana Health took in during FY2025, followed through to profit: what it cost to make, what went on running the business, and what was left after tax.

  1. Revenue $3.2B
  2. Selling, general and admin $217M · 6.8%
  3. Other operating costs $2.9B · 90.7%
  4. Operating income $78.5M · 2.5%
  5. Interest and other $40.5M · 1.3%
  6. Net income $22.5M · 0.7%

Shares of revenue. Source: Astrana Health's 10-K for FY2025, as filed with the SEC. "Other" lines are what the reported lines leave unexplained.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2011 Jan 2011 2012 Jan 2012 2013 Jan 2013 2014 Jan 2014 2015 Mar 2015 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 4 5 8 10 33 306 356 520 561 687 774 1,144 1,387 2,035 3,182 3,844
Gross profit 1 1 1 1 — — 83 159 93 148 178 — — — — —
EBITDA 0 −0 −2 −4 −0 30 54 108 51 99 116 122 102 117 124 163
Operating income 0 −0 −2 −4 −1 12 35 88 32 81 98 104 85 89 79 100
Net income −0 −1 −9 −5 −2 11 26 11 14 38 69 45 61 43 22 41
Diluted EPS −$0.01 −$0.20 −$2.70 −$1.37 −$0.37 $0.41 $0.90 $0.29 $0.39 $1.01 $1.52 $0.99 $1.29 $0.90 $0.46 $0.82
Growth (year on year)
Revenue — +31.2% +52.2% +34.8% +214.7% +827.4% +16.5% +45.9% +7.8% +22.6% +12.6% +47.8% +21.2% +46.7% +56.4% +58.9%
EBITDA — — — — — — +81.9% +98.7% −52.9% +95.0% +17.0% +5.3% −16.0% +14.6% +6.0% +64.8%
Operating income — — — — — — +200.7% +151.6% −63.3% +148.3% +22.0% +6.2% −18.8% +5.6% −12.1% +43.4%
Net income — — — — — — +125.3% −58.0% +30.3% +167.0% +82.9% −34.5% +34.4% −28.9% −47.9% —
Diluted EPS — — — — — — +119.5% −67.8% +34.5% +159.0% +50.5% −34.9% +30.3% −30.2% −48.9% —
Margins
Gross margin 14.9% 19.1% 18.8% 13.4% — — 23.3% 30.5% 16.6% 21.5% 23.0% — — — — —
EBITDA margin 0.4% −7.8% −26.5% −37.0% −1.1% 9.7% 15.2% 20.7% 9.0% 14.4% 14.9% 10.6% 7.4% 5.8% 3.9% 4.3%
Operating margin 0.1% −8.1% −26.7% −37.3% −2.1% 3.8% 9.9% 17.0% 5.8% 11.7% 12.7% 9.1% 6.1% 4.4% 2.5% 2.6%
Net margin −4.0% −14.1% −114.5% −47.9% −5.5% 3.7% 7.2% 2.1% 2.5% 5.5% 8.9% 3.9% 4.4% 2.1% 0.7% 1.1%
Free-cash-flow margin −6.8% −7.7% 0.2% −14.3% −1.0% 6.1% 14.0% 4.7% 2.3% 6.5% 6.6% 5.2% 2.9% 2.2% 3.3% 2.5%
Cash flow
Cash from operations −0 −0 0 −1 −0 22 52 25 14 46 70 82 68 52 115 108
Capital spending 0 0 0 0 0 3 2 1 1 1 19 23 29 8 10 13
Free cash flow −0 −0 0 −2 −0 19 50 24 13 45 51 59 40 44 104 94
Stock-based pay 0 0 2 0 1 2 3 1 2 3 7 16 22 35 39 41
Free cash flow after stock pay −0 −1 −2 −2 −2 17 47 23 11 42 44 43 18 10 66 54
Balance sheet
Cash — — — — — 55 100 107 103 193 233 288 294 288 429 401
Total debt — — — — 11 — 5 0 251 246 188 207 282 438 1,052 948
Net debt (negative = net cash) — — — — — −55 −95 −107 148 52 −45 −81 −12 150 623 548
Diluted shares — 3m 3m 4m 5m 28m 29m 38m 36m 37m 45m 46m 47m 48m 49m 49m
Returned to shareholders
Dividends — — — — — 27 10 18 62 51 31 14 62 4 8 2
Buybacks — — — 0 0 1 3 5 8 1 6 9 10 1 26 18
Total returned — — — 0 0 27 14 23 69 52 37 23 72 5 33 20

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

1 of 7 checks passed · June 30, 2026
What it owns · $2.3bn
Short-term assets $919mLonger-term assets $1.4bn
What it owes, and who funded it · $2.5bn
Short-term liabilities $748mLonger-term liabilities $936mShareholders' equity $830m
  • Short-term assets cover short-term liabilities $919m of assets due within a year against $748m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $919m short-term assets against $936m of longer-dated liabilities.
  • More cash than debt $401m of cash against $936m of debt.
  • Debt below 40% of shareholders' equity Debt is 113% of equity.
  • Debt burden no higher than five years ago Debt to equity moved from 41% to 113% over five years.
  • A year's operating cash flow covers at least 20% of debt $108m of operating cash flow against $936m of debt.
  • Operating profit covers interest at least five times over Operating income of $100m against $67m of interest.

From Astrana Health, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

FY2026 Q2 TTM
Buybacks (TTM)
$17.8M
Dividends (TTM)
$1.9M
Returned to shareholders
21%
of free cash flow
Buybacks, last 3 fiscal years
$36.7M
Diluted share count
+1.8%
year over year
Total shareholder yield
1.1%
dividends 0.1% + buybacks 1.0% of market value
Dividend payout ratio
5%
of net income paid out
Days sales outstanding
44 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in health care services
Last 12 months unless stated ASTH AMN CHE AVAH OPCH HIMS Median
Revenue, last 12 months $3.8bn $3.4bn $2.7bn $2.6bn $5.7bn $2.6bn $1.2bn
Revenue growth, last 12 months 58.9% 24.0% 5.2% 19.5% 5.9% 28.0% 7.3%
Revenue growth, 3-year average 43.7% −7.8% 6.1% 12.4% 11.3% 53.7% 11.3%
Revenue growth, latest quarter 48.5% 2.3% 10.6% 13.7% 1.9% 38.2% 8.5%
Gross margin 21.5% 27.8% 33.5% 32.3% 19.1% 68.4% 27.9%
Operating margin 2.6% 5.8% 13.9% 10.5% 5.9% −6.0% 2.3%
Operating margin, 3-year average 3.8% 0.5% 14.4% 7.0% 6.3% 0.5% 2.3%
Net margin 1.1% 3.1% 10.6% 10.6% 3.7% −5.5% 1.2%
Cash from operations / revenue 2.8% 13.7% 13.6% 6.5% 6.1% 10.2% 6.1%
Free-cash-flow margin 2.5% 12.8% 11.1% 6.0% 5.3% 2.4% 5.1%
Free-cash-flow margin, 3-year average 3.5% 9.5% 11.6% 3.2% 4.7% — 3.6%
Stock pay / revenue 1.1% 0.9% — 0.7% 0.7% 6.0% 1.1%
Change in share count 1.8% 2.1% −8.3% 11.4% −5.7% 0.3% 0.3%

Median of all 41 companies we cover in health care services. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

41 health care services companies
Measure Company Peer median Rank
Revenue growth Growth 58.9% 7.3% 2 of 41
Change in growth rate Growth +2.2pp +1.1pp 16 of 41
Operating margin Profitability 2.6% 2.6% 20 of 40
Net margin Profitability 1.1% 1.2% 22 of 41
Free-cash-flow margin Cash generation 2.5% 5.1% 26 of 40
Stock pay as % of revenue Cash generation 1.1% 0.9% 19 of 35
Long-term debt as % of assets Balance sheet 38.7% 27.7% 24 of 31
Change in share count Balance sheet 1.8% 0.4% 25 of 39
Days sales outstanding Balance sheet 44 days 39 days 20 of 31

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Health Care Capitation Revenue $2.9B 91.9% ▲ 57.5%
Health Care Patient Service $113M 3.5% ▲ 80.7%
Health Care Other $86.2M 2.7% 0.0%
Management Service $30.4M 1.0% ▲ 117.4%
Other $28.3M 0.9% ▲ 85.8%

From Astrana Health, Inc.'s 10-K filed March 12, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$1.5B
Institutions reporting
207
Shares held vs prior quarter
▲ 7.4%
Positions opened / closed
55 / 17

Top buyers and sellers, Q2 2026: 135 institutions bought and 66 sold ; the biggest buyer was Blackrock, Inc (+736K shares) and the biggest seller 683 Capital Management, LLC (−490K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Blackrock, Inc. $320M 6.9M 21.5% ▲ 11.9%
Vanguard Portfolio Management LLC $121M 2.6M 8.1% ▲ 14.4%
Vanguard Capital Management LLC $90.3M 1.9M 6.1% ▲ 13.8%
State Street Corp $80.7M 1.7M 5.4% ▲ 5.4%
325 Capital LLC $74.9M 1.6M 5.0% ▼ 12.2%
Dimensional Fund Advisors LP $68.1M 1.5M 4.6% ▲ 7.3%
Wellington Management Group LLP $60M 1.3M 4.0% ▼ 3.7%
Geode Capital Management, LLC $54.2M 1.2M 3.6% ▲ 12.5%
Bank Of America Corp $39.5M 852K 2.7% ▲ 48.3%
FMR LLC $31.8M 686K 2.1% ▲ 64.8%
Wells Fargo & Company $30.9M 665K 2.1% ▲ 545.6%
Charles Schwab Investment Management Inc $30.3M 653K 2.0% ▲ 1.3%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Astrana Health, Inc.'s complete shareholder register. Values are as reported by the filers ; 1 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $0 net buying

No open-market insider trades reported in the last 12 months.

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Trades by members of Congress

All 2 trades and filings

No trades in Astrana Health, Inc. disclosed in the last 12 months; 2 earlier trades on record.

  • Judy Chu(D-CA 28):Purchase, $100,001 - $250,000, traded August 19, 2025, filed August 30, 2025
  • Judy Chu(D-CA 28):Sale (full), $100,001 - $250,000, traded August 19, 2025, filed August 30, 2025

Value ranges as filed; reports can arrive up to 45 days after a trade.

Earnings dates and SEC filings

Results announcements

Next expected around November 5, 2026 estimated from the company's past filing pattern, not announced

  • August 6, 2026
  • May 7, 2026
  • March 2, 2026
  • November 6, 2025
  • August 7, 2025
  • July 2, 2025

Recent SEC filings

Data status

When each part of this page on Astrana Health, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Astrana Health, Inc. in brief

What does Astrana Health, Inc. do?
Astrana Health, Inc. is a US-listed company in the health care services industry. Its financial year ends in December.
What is Astrana Health, Inc.'s stock ticker?
Astrana Health, Inc. trades under the ticker ASTH on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Astrana Health, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Astrana Health, Inc. reported revenue of $3.8B, 58.9% higher than a year earlier, according to its SEC filings.
What is Astrana Health, Inc.'s free cash flow?
Astrana Health, Inc.'s free-cash-flow margin is 2.5% of revenue over the trailing twelve months, ranking 26 of the 40 health care services companies we cover.
Who are Astrana Health, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Blackrock, Inc., Vanguard Portfolio Management LLC and Vanguard Capital Management LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Is Astrana Health, Inc. buying back stock, and does it pay a dividend?
Astrana Health, Inc. spent $17.8M on share repurchases over the trailing twelve months, and its diluted share count still rose 1.8% over the year.
What is Astrana Health, Inc.'s market cap?
On November 2, 2026, Astrana Health, Inc.'s market capitalisation was about $1.8B, with a price-to-earnings ratio of 45.0 and net debt of $548M. Market figures come from third-party market data and may be delayed.
Does Astrana Health, Inc. pay a dividend?
Yes: Astrana Health, Inc. paid $1.9M in dividends over the trailing twelve months, a dividend yield of 0.10% and a payout ratio of 4.6%.
How much debt does Astrana Health, Inc. have?
Astrana Health, Inc.'s debt-to-equity ratio is 112.8%, from its latest balance sheet (40.8% five years earlier). The financial health section below sets out its other solvency checks.
Who are Astrana Health, Inc.'s competitors?
In our Health Care Services peer group, the companies closest to Astrana Health, Inc. are AMN Healthcare Services Inc, Chemed Corp, Aveanna Healthcare Holdings, Inc., Option Care Health, Inc. and Hims & Hers Health, Inc. The side-by-side comparison below sets their revenue, margins and growth against Astrana Health, Inc.'s.
When is Astrana Health, Inc.'s next earnings date?
Around November 5, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Astrana Health, Inc. announces its own schedule.